BDBM221630 US9303045, 126::US9695195, 126

SMILES CN1C2COCC1CC(C2)NC(=O)c1nn(CC(F)(F)F)c2ccccc12

InChI Key InChIKey=UVOXGHSCUXGFPR-UHFFFAOYSA-N

Data  3 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 3 hits for monomerid = 221630   

Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221630(US9303045, 126 | US9695195, 126)
Affinity DataIC50:  0.860nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221630(US9303045, 126 | US9695195, 126)
Affinity DataIC50:  0.860nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221630(US9303045, 126 | US9695195, 126)
Affinity DataIC50:  0.680nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent